Allegion CFO Michael Wagnes Exercises Stock Options and Sells Shares Under Pre-Arranged Trading Plan

CFO's Coordinated Option Exercise and Share Sale Activity

Michael Wagnes, the Senior Vice President and Chief Financial Officer of Allegion plc, executed a carefully coordinated series of transactions involving the company's ordinary shares on July 23, 2026. The filing indicates that Wagnes exercised stock options to acquire shares and immediately sold a corresponding number of shares on the same trading date. This type of coordinated activity—acquiring shares through options and selling them in the open market on the same day—is commonly used by executives to realize gains from vested options while managing their overall position in the company's securities.

The transactions were conducted pursuant to a Rule 10b5-1 trading plan that Wagnes had adopted on September 12, 2025. Rule 10b5-1 plans allow company insiders to establish predetermined trading instructions during periods when they are not in possession of material non-public information, providing a documented affirmative defense against insider trading allegations. The pre-arranged nature of these transactions indicates that the decisions regarding timing, quantity, and pricing were made months in advance of the execution date.

Details of Stock Option Exercises and Pricing

The filing discloses two separate stock option exercises by Wagnes on July 23, 2026. The first transaction involved the exercise of 1,716 ordinary shares at a strike price of $71.835 per share. These options were exercisable immediately, having vested in equal annual installments on February 13, 2018, February 13, 2019, and February 13, 2020. The second option exercise covered 1,468 ordinary shares at a strike price of $86.93 per share, with these options having vested in equal annual installments on February 22, 2019, February 22, 2020, and February 22, 2021.

Combined, the two option exercises resulted in the acquisition of 3,184 ordinary shares. The strike prices of the exercised options—$71.835 and $86.93—represented the fair market value of Allegion's ordinary shares at the time the options were originally granted, which is standard practice for equity compensation arrangements. The exercise of these fully vested options added to Wagnes' holdings in the company, though the subsequent sale of shares on the same day resulted in a net change to his beneficial ownership position.

Share Sale Transactions and Execution Prices

On the same date as the option exercises, Wagnes sold 3,184 ordinary shares of Allegion plc at a price of $150.98 per share. This sale price was substantially higher than the strike prices of the exercised options, reflecting the appreciation in Allegion's share value between the time the options were granted and the date of exercise and sale. The higher sale price compared to the exercise prices represents the economic gain realized through the option exercise and immediate liquidation strategy.

The sales were executed in two separate lots matching the two option exercises: 1,716 shares were sold following the first option exercise, and 1,468 shares were sold following the second option exercise. All shares sold were owned directly by Wagnes, as indicated by the "D" designation in the ownership form field of the disclosure. The filing notes that these sales were also effected pursuant to the same Rule 10b5-1 trading plan adopted on September 12, 2025, confirming that both the acquisition and disposition sides of these transactions were part of the pre-arranged trading schedule.

Changes to Beneficial Ownership Position

Following the completion of all transactions on July 23, 2026, Wagnes' beneficial ownership position in Allegion plc was 31,299 ordinary shares held directly. This figure represents his total beneficial ownership after accounting for the shares acquired through option exercises and the shares sold on the reporting date. The disclosure indicates that his direct ownership remained the same after the transactions because the number of shares acquired through option exercises (3,184) was offset by the number of shares sold (3,184).

Despite the net zero change to his share count, the transactions had economic significance for Wagnes. By exercising options at lower strike prices and selling at the higher market price of $150.98, he realized substantial gains. The difference between the weighted average exercise price and the sale price represented meaningful value realization. Investors monitoring insider transactions often pay attention to such coordinated exercises and sales, as they can provide insights into management's views on current share valuation and liquidity needs.

Rule 10b5-1 Trading Plan Framework and Governance

The utilization of a Rule 10b5-1 trading plan by Wagnes reflects established practices in corporate governance and insider trading compliance. These plans, authorized under Rule 10b5-1(c) of the Securities Exchange Act of 1934, allow corporate insiders to establish predetermined trading arrangements during open trading windows or when they are not in possession of material non-public information. Once adopted, the plan operates automatically according to its terms, removing the need for real-time trading decisions that might otherwise raise concerns about the timing or motivation of trades.

Wagnes' plan, adopted on September 12, 2025, appears to have been designed to provide for periodic option exercises and share sales over a defined period. The July 23, 2026 transactions represent executions under this pre-established arrangement. By filing this Form 4 disclosure, Allegion plc and Wagnes are providing transparency to investors regarding insider transactions. The clear documentation of the pre-arranged trading plan in the filing underscores compliance with regulatory requirements and demonstrates that the transactions were not motivated by access to material non-public information.

Allegion's Executive Compensation Structure

The option exercises disclosed in this filing reflect standard components of executive compensation at Allegion plc. Stock options represent a common long-term incentive vehicle used by public companies to align the economic interests of executives with those of shareholders. By granting options with strike prices at fair market value on the grant date, the company encourages executives like Wagnes to focus on driving share price appreciation over the vesting period. The vesting schedule disclosed in the filing—with options vesting in equal annual installments over three years—is typical for executive equity awards and ensures that executives maintain an ongoing stake in the company's performance.

The fact that Wagnes held multiple tranches of options granted at different times, with different strike prices and vesting dates, is consistent with standard practice in multi-year executive compensation programs. Companies typically grant new options annually or as part of regular compensation reviews, creating a portfolio of options at different stages of vesting. Wagnes' exercise of fully vested options on July 23, 2026, and the subsequent sale of the underlying shares, represents a common liquidity management strategy employed by executives who receive significant equity compensation.

Transparency and Regulatory Compliance Disclosure

The filing of this Form 4 statement fulfills Wagnes' disclosure obligations under Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and beneficial owners of more than 10 percent of a company's securities to report changes in their beneficial ownership within two business days of the transaction. In this case, the disclosure was filed on July 27, 2026, three business days after the July 23, 2026 transactions, meeting the regulatory timeline requirements. The document was executed on behalf of Wagnes by Tandra M. Foster, identified as Attorney-in-Fact, indicating that Wagnes had authorized representation in executing the filing.

The disclosure provides complete transparency regarding the transactions, including the exact dates, transaction codes, number of securities, pricing, and the resulting beneficial ownership position. The detailed explanation of responses clarifies that both the option exercises and the share sales were effected pursuant to the Rule 10b5-1 trading plan adopted on September 12, 2025. This level of detail in regulatory disclosures is designed to ensure that investors and market participants have access to accurate information about insider trading activity at public companies, enabling them to make informed investment decisions.

What Investors Should Monitor

Investors holding Allegion plc securities may wish to monitor continued insider trading activity by Wagnes and other company executives. While the coordinated exercise and sale reported in this filing does not necessarily indicate any particular view about the company's future prospects—given that it was part of a pre-arranged plan established months earlier—patterns of insider trading can sometimes provide useful context when analyzed alongside other corporate developments and market conditions. Regular monitoring of Form 4 filings can help investors stay informed about executive transactions and changes in insider shareholdings.

The immediate share price impact was not clear from available public information. The disclosure shows historical prices associated with the transactions (the option exercise prices and the sale price), but does not indicate how the market may have reacted to this insider activity or any other concurrent developments at the company. Investors seeking to understand the full context of these transactions and their potential implications should review them alongside other company disclosures, earnings reports, and market analysis.